Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

Clinical trial NCT04949256 · TERMINATED

Trial details

NCT number: NCT04949256
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Esophageal Squamous Cell Carcinoma

Start date: 2021-07-28
Primary completion: 2025-05-08
Enrollment: 863

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.